Cullen Capital Management LLC Has $12.59 Million Holdings in Sanofi (NASDAQ:SNY)

Cullen Capital Management LLC lowered its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 261,112 shares of the company's stock after selling 29,423 shares during the period. Cullen Capital Management LLC's holdings in Sanofi were worth $12,593,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in Sanofi in the fourth quarter valued at about $135,933,000. Boston Partners raised its position in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC boosted its stake in Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after buying an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock valued at $93,774,000 after acquiring an additional 514,542 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on SNY shares. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Price Performance

Shares of SNY stock traded down $1.98 during midday trading on Thursday, reaching $49.23. 1,355,277 shares of the company were exchanged, compared to its average volume of 2,314,126. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $124.38 billion, a P/E ratio of 19.73, a PEG ratio of 1.01 and a beta of 0.57. The company's 50 day moving average price is $55.08 and its two-hundred day moving average price is $52.47.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.